These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 21410627

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
    Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ, Sitagliptin Study 049 Group.
    Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G.
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [Abstract] [Full Text] [Related]

  • 7. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
    Engel SS, Seck TL, Golm GT, Meehan AG, Kaufman KD, Goldstein BJ.
    Endocr Pract; 2013 Dec; 19(5):751-7. PubMed ID: 23757615
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Jan; 14(1):67-76. PubMed ID: 22050786
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
    Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P.
    Diabetes Technol Ther; 2013 Mar; 15(3):214-22. PubMed ID: 23427864
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, Engel SS, Kaufman KD, Goldstein BJ.
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [Abstract] [Full Text] [Related]

  • 18. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW, Gemigliptin Study 006 Group.
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.